Citadel Advisors
EGRX

Citadel Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Citadel Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-900
Closed -$3.36K – 15775
2024
Q3 		$3.36K Buy
+900
New +$4.29K ﹤0.01% 13664
2024
Q2 		– Sell
-3,000
Closed -$15.7K – 15696
2024
Q1 		$15.7K Sell
3,000
-2,000
-40% -$11K ﹤0.01% 13169
2023
Q4 		$26.1K Buy
5,000
+3,600
+257% +$35.5K ﹤0.01% 12387
2023
Q3 		$22.1K Sell
1,400
-1,500
-52% -$26.9K ﹤0.01% 12545
2023
Q2 		$56.4K Buy
2,900
+1,200
+71% +$28.5K ﹤0.01% 11664
2023
Q1 		$48.2K Sell
1,700
-58,400
-97% -$1.73M ﹤0.01% 12198
2022
Q4 		$1.76M Sell
60,100
-75,600
-56% -$2.4M ﹤0.01% 5718
2022
Q3 		$3.58M Buy
+135,700
New +$4.98M ﹤0.01% 4458
2022
Q1 		– Sell
-5,000
Closed -$255K – 14809
2021
Q4 		$255K Sell
5,000
-700
-12% -$36.3K ﹤0.01% 11306
2021
Q3 		$318K Buy
+5,700
New +$280K ﹤0.01% 10944
2020
Q4 		– Sell
-13,800
Closed -$586K – 11657
2020
Q3 		$586K Buy
+13,800
New +$604K ﹤0.01% 7007
2019
Q2 		– Sell
-9,800
Closed -$495K – 10006
2019
Q1 		$495K Buy
9,800
+4,300
+78% +$191K ﹤0.01% 6800
2018
Q4 		$222K Sell
5,500
-13,900
-72% -$716K ﹤0.01% 7717
2018
Q3 		$1.34M Buy
19,400
+6,300
+48% +$478K ﹤0.01% 5040
2018
Q2 		$991K Sell
13,100
-1,200
-8% -$75.5K ﹤0.01% 5233
2018
Q1 		$753K Sell
14,300
-3,300
-19% -$192K ﹤0.01% 5230
2017
Q4 		$940K Buy
17,600
+1,000
+6% +$55.7K ﹤0.01% 4740
2017
Q3 		$990K Buy
16,600
+11,700
+239% +$708K ﹤0.01% 4341
2017
Q2 		$387K Sell
4,900
-10,400
-68% -$851K ﹤0.01% 5501
2017
Q1 		$1.27M Buy
15,300
+11,800
+337% +$877K ﹤0.01% 3648
2016
Q4 		$278K Sell
3,500
-1,600
-31% -$116K ﹤0.01% 5794
2016
Q3 		$357K Sell
5,100
-16,300
-76% -$903K ﹤0.01% 5377
2016
Q2 		$830K Sell
21,400
-13,000
-38% -$541K ﹤0.01% 3795
2016
Q1 		$1.39M Buy
34,400
+31,500
+1,086% +$2M ﹤0.01% 3078
2015
Q4 		$257K Sell
2,900
-5,600
-66% -$442K ﹤0.01% 5451
2015
Q3 		$629K Buy
8,500
+5,600
+193% +$466K ﹤0.01% 4463
2015
Q2 		$234K Buy
+2,900
New +$189K ﹤0.01% 6109

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Citadel Advisors's EGRX Position: Q4 2024 in Review

Citadel Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 26,013 shares — an estimated $97K sold.

Citadel Advisors first reported a position in EGRX in Q1 2015 and held it in 37 quarters. The position peaked at $20.7M in Q3 2018. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Citadel Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 26,013 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $97K.
  • Citadel Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 37 quarters.
  • Citadel Advisors's Eagle Pharmaceuticals, Inc. position peaked at $20.7M in Q3 2018.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.